Apyx Medical Corporation updated earnings guidance for the year ending December 31, 2023. For the year, company expects Total revenue in the range of $59.0 million to $62.0 million, representing growth of approximately 33% to 39% year-over-year, compared to total revenue of $44.5 million for the year ended December 31, 2022. The Company's prior guidance range for total revenue was $58.0 million to $61.0 million, representing growth of 30% to 37% year-over-year.

Net loss attributable to stockholders of approximately $10.5 million, compared to $23.2 million for the year ended December 31, 2022. The Company's prior guidance for net loss attributable to stockholders was approximately $14.0 million.